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Sorafenib is a multikinase inhibitor thought to target vascular endothelial growth factor and its receptor.
The European Medicines Agency (EAMA) and Food and Drug Administration (FDA) approved the use
of sorafenib in late-stage hepatic cellular cancer (HCC) on October 30, 2007, and November 19, 2007,
respectively. It is the only drug approved for use in the systematic treatment of primary HCC, and it offers
renewed hope for middle- and late-stage liver cancer patients. Conventional use of sorafenib is 400 mg orally,
twice daily, until tumor progression or patient death. The following is a report of a serious episode of skin
rash in a liver cancer patient at our hospital subsequent to treatment with sorafenib.
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A
47-year-old woman with a 10-year history of
hepatitis B diagnosed with second clinical stage
hepatic cellular cancer (HCC) of (T2N0M0),
combined with cirrhosis, medium ascites, and portal
hypertension, presented at the hospital. Surgical resection
or interventional therapy was not advisable for the
patient, and the patient was started solely on oral
‘sorafenib’, 400 mg twice daily.
After taking sorafenib for a week, skin rash appeared
on her head, face, back, and waist, manifested as skin
rhagadia, maculopapule, and acneiform skin rash,
combined with vesicle and seepage (Fig. 1). Vaseline
and urea cream were repeatedly smeared on the skin
after a wash with physiological saline; sorafenib was
continued. The skin scabbed and the symptoms of
redness and swelling disappeared (Fig. 2). Skin rhagadia
on the head and face reduced over a 2-month period,
and the general health of the patient improved. The
patient was advised to take 400 mg of sorafenib, twice
daily (Fig. 3).
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Fig. 1. Following sorafenib treatment, skin rash began to
appear. (A) Skin rash on the patient’s waist. (B) Skin rash on
the patient’s face, after treatment with Vaseline and urea
cream.
Fig. 2. The skin scabbed and the symptoms of redness and
swelling disappeared after 2 months.
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Learning points
1) Sorafenib can cause terrible skin rash. There is
evidence from previous studies that skin reactions
correlate positively with the efficacy of drugs (13).
2) The most potent way of treating skin rash is washing
it with physiological saline to keep the skin clean
and applying vaseline and moisturizer to keep the
skin moist.
3) Even with serious skin rash, sorafenib may be
continued during treatment.
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Fig. 3. The skin rash and scabbing improved gradually on
the patient’s face and waist, 6 months after onset.
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